Metabolic modulator is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
=== Development === In Nicotiana attenuata HypSys is known to not be involved in defence against insect herbivores. Silencing and over-expression of HypSys does not affect the feeding performance of larvae compared to normal plants. Berger silenced HypSys and found that it caused changes in flower morphology which reduced the efficiency of self-pollination. The flowers had pistils that protruded beyond their anthers, a similar phenotype to CORONATINE-INSENSITIVE1-silenced plants which lack a jasmonate receptor. Measurement of jasmonate levels in the flowers revealed that they were lower than in normal plants. The authors suggested that HypSys peptides in N. attenuata have diversified from their function as defence related peptides to being involved in controlling flower morphology. The signalling processes remain similar however, being mediated through jasmonates. Systemin also increases root growth in Solanum pimpinellifolium suggesting that it may also play some role in plant development.
The submarines were under orders to report sightings before attempting to attack, so Flying Fish waited until nightfall, then surfaced to radio in its report. Fifth Fleet commander Spruance was convinced that a major battle was at hand. After consulting with Nimitz at Pacific Fleet Headquarters in Hawaii, he ordered Rear Admiral Marc Mitscher, commander of the Fast Carrier Task Force (Task Force 58), who had sent two carrier task groups north to intercept aircraft reinforcements from Japan, to reform and move west of Saipan into the Philippine Sea. TF 52's battleships, cruisers and escort carrier groups were ordered to remain near Saipan to protect the invasion fleet and provide air support for the landings. Shortly before midnight on 18 June Nimitz radioed Spruance that a Japanese vessel had broken radio silence. The message intercepted was an apparent dispatch from Ozawa to his land-based air forces on Guam. Radio direction-finding placed the sender approximately 355 miles (571 km) west-southwest of TF 58. Mitscher considered whether the radio messages were a Japanese deception, as the Japanese were known to send a single vessel off to break radio silence, to mislead their adversaries about the actual location of the main force. Mitscher realized that there was a chance of a night surface encounter with Ozawa's forces. Arleigh Burke, Mitscher's chief of staff (a former destroyer squadron commander who had won several night battles in the Solomons), assumed that battle line commander Willis Lee would welcome the opportunity. But Lee strongly opposed such an encounter.
=== Mitochondria === ASD could be linked to mitochondrial disease, a basic cellular abnormality with the potential to cause disturbances in a wide range of body systems. A 2012 meta-analysis study, as well as other population studies show that approximately 5% of autistic children meet the criteria for classical mitochondrial dysfunction. It is unclear why this mitochondrial disease occurs, considering that only 23% of children with both ASD and mitochondrial disease present with mitochondrial DNA abnormalities.
Analysing these large varieties of protein species at very minute concentrations is difficult and requires extremely sensitive equipment which has not been fully developed yet. The reason that HCP levels need to be monitored is due to the uncertain effects they have on the body. At trace amounts, the effects of HCPs on patients are unknown and specific HCPs may affect protein stability and drug effectiveness, or cause immunogenicity in patients. If the stability of the drug is affected, durability of the active substance in the pharmaceutical product could decrease. The effects that the drug is intended to have on patients could also possibly be increased or decreased, leading to health complications that may arise. The degree of immunogenicity on a long-term basis is difficult, and almost impossible, to determine and consequences can include severe threats to the patient’s health.
== G == G protein - G protein-coupled receptor - G3P - GABA - GABA receptor - GABA-A receptor - gag-onc fusion protein - galanin - gamete - gamma-chain immunoglobulin - gamma-delta T-cell antigen receptor - gastrin - gastrointestinal hormone receptor - gastrula - gel electrophoresis - gene - gene expression - gene pool - gene regulatory network - genetic carrier - genetic code - genetic drift - genetic engineering - genetic fingerprint - genetic recombination - genetics - genome - genomics - genotype - glial fibrillary acidic protein - globin - glucagon - glucagon receptor - glucocorticoid receptor - glucose - glutamate - glutamate receptor - glutamic acid - glutamine - glycerine - glycine - glycine receptor - glycolipid - glycolysis - glycoprotein - gonadorelin - gradient - granulocyte colony-stimulating factor - granulocyte colony-stimulating factor receptor - granulocyte-macrophage colony-stimulating factor - granulocyte-macrophage colony-stimulating factor receptor - granzyme - growth factor receptor - GTP-binding protein - GTPase
Sources: en.wikipedia.org
The term narcotic (, from ancient Greek ναρκῶ narkō, "I make numb") originally referred medically to any psychoactive compound with numbing or paralyzing properties. In the United States, it has since become associated with opiates and opioids, commonly morphine and heroin, as well as derivatives of many of the compounds found within raw opium latex. Legally speaking, the term "narcotic" may be imprecisely defined and typically has negative connotations. When used in a legal context in the U.S., a narcotic drug is totally prohibited, such as heroin, or one that is used in violation of legal regulation (in this word sense, equal to any controlled substance or illicit drug). In the medical community, the term is more precisely defined as a synonym of opioids and generally does not carry the same negative connotations. Statutory classification of a drug as a narcotic often increases the penalties for violation of drug control statutes. For example, although U.S. federal law classifies both cocaine and amphetamines as "Schedule II" drugs, the penalty for possession of cocaine is greater than the penalty for possession of amphetamines because cocaine, unlike amphetamines, is classified as a narcotic. Research acknowledges that alcohol can have similar effects to narcotics in head or trunk trauma situations.
IC-26 (WIN 1161-3, Methiodone) is an analogue of the opioid analgesic methadone, where the carbonyl group has been replaced by the bioisosteric sulfone group. Human and animal studies suggest that IC-26 is around the same potency as methadone, although other studies have found its activity to be inconsistent between different patients, with consistent opioid activity only being seen at a dose several times that of methadone. IC-26 was assessed for its abuse potential, but despite being found to have similar potential to morphine for development of dependence it was never placed under international control as an illegal drug.
This model attempts to use these factors to predict the impact of lifestyle changes and genetics for the evolution of the MASLD pathology. Many researchers describe MASLD as a multisystem disease, as it impacts and is influenced by organs and regulatory pathways other than the liver. The accumulation of senescent cells in the liver is seen in persons with MASLD. In mice, liver senescent hepatocytes result in increased liver fat deposition. Treatment of MASLD mice with senolytic agents has been shown to reduce hepatic steatosis. Based on gene knockout studies in murine models, it has been suggested that, among many other pathogenic factors, TGF beta signals may be crucially involved in promoting the progression of MASH.
=== Advantages and disadvantages === There is a wide variety of biological insecticides with differing attributes, but in general the following has been described. They are easier, faster and cheaper to register, usually with lower mammalian toxicity. They are more specific, and thus preserve beneficial insects and biodiversity in general. This makes them compatible with IPM regimes. They degrade rapidly causing less impact on the environment. They have a shorter withholding period. The spectrum of control is narrow. They are less effective and prone to adverse ambient conditions. They degrade rapidly and are thus less persistent. They are slower to act. They are more expensive, have a shorter shelf-life, and are more difficult to source. They require more specialised knowledge to use.
=== Serie A: 2021–2024 === Salernitana's first match in its return to the top flight was a 3–2 defeat against Bologna on 22 August 2021. After a poor start to the season, earning only one point from the first six matches, the club picked up its first Serie A victory against Genoa on matchday seven, winning 1–0 courtesy of a goal from Milan Đurić. In October, the Salernitana board fired Castori after a 2–1 loss to Spezia had left the club at the bottom of the table, with four points from their opening eight league games. Stefano Colantuono was named as his replacement, returning for a second spell as head coach having previously led Salernitana from December 2017 to December 2018. On 22 May 2022, Salernitana avoided relegation by finishing with the lowest points tally in Serie A history with just 31 points. Salernitana managed to pull off the great escape by securing 18 points from their last 15 matches. In the 2023/2024 Serie A season, Salernitana finished bottom of the table and were relegated back to Serie B. In the 2024-25 season, Salernitana finished 16th, and were sent to the relegation playoffs, losing to Sampdoria 3-0, relegating to Serie C.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.